|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Genetic variation of hepatitis B virus and its significance forpathogenesis显示文摘Hepatitis B virus(HBV)has a worldwide distribution and is endemic in many populations.Due to its unique life cycle which requires an error-prone reverse transcriptase for replication,it constantly evolves,resulting in tremendous genetic variation in the form of genotypes,sub-genotypes,and mutations.In recent years,there has been considerable research on the relationship between HBV genetic variation and HBV-related pathogenesis,which has profound implications in the natural history of HBV infection,viral detection,immune prevention,drug treatment and prognosis.In this review,we attempted to provide a brief account of the influence of HBV genotype on the pathogenesis of HBV infection and summarize our current knowledge on the effects of HBV mutations in different regions on HBV-associated pathogenesis,with an emphasis on mutations in the pre S/S proteins in immune evasion,occult HBV infection and hepatocellular carcinoma(HCC),mutations in polymerase in relation to drug resistance,mutations in HBV core and e antigen in immune evasion,chronicalization of infection and hepatitis B-related acute-on-chronic liver failure,and finally mutations in HBV x proteins in HCC. | Zhen-Hua Zhang Chun-Chen Wu Xin-Wen Chen Xu Li Jun Li Meng-Ji Lu | 2016 | World Journal of Gastroenterology2016，22，1： | 22 |
| 2 | 阻断PD-L1/PD-1途径增强顺铂化疗效果的实验研究显示文摘目的:探讨抗PD-1抗体阻断PD-L1/PD-1途径对顺铂的抗肿瘤效应以及抗肿瘤免疫力的影响。方法:建立TC-1肿瘤细胞C57BL/6小鼠模型,分为4组(n=4),绘制肿瘤生长曲线及小鼠生存曲线,并取肿瘤组织,免疫组化法检测肿瘤组织中PD-L1、CD8^+T细胞的表达。结果:(1)顺铂组、PD-1组及联合用药组均可显著抑制肿瘤生长及延长小鼠生存时间,联合用药组效果最为明显(P<0.05)。(2)顺铂组肿瘤组织PD-L1表达显著增加,联合用药组PD-L1表达显著下降(P<0.05)。(3)顺铂组肿瘤组织中CD8^+T细胞减少,联合用药组CD8^+T细胞表达显著增加(P<0.05)。结论:PD-1抗体阻断PD-L1/PD-1通路联合顺铂可提高机体抗肿瘤免疫,发挥免疫细胞抗肿瘤效应,增强顺铂的化疗效果。 | 魏洁 寇蓬 廉阳秧 梁宏 杨丽华 | 2016 | 实用医学杂志2016，32，1： | 11 |
| 3 | Clinical significance of hepatitis B surface antigen mutants显示文摘Hepatitis B virus(HBV) infection is a major public health problem in many countries, with nearly 300 million people worldwide carrying HBV chronic infection and over 1 million deaths per year due to cirrhosis and liver cancer. Several hepatitis B surface antigen(HBs Ag) mutations have been described, most frequently due to a single amino acid substitution and seldom to a nucleotide deletion. The majority of mutations are located in the S region, but they have also been found in the pre-S1 and pre-S2 regions. Single amino acid substitutions in the major hydrophilic region of HBs Ag, called the 'a' determinant, have been associated with immune escape and the consequent failure of HBV vaccination and HBs Ag detection, whereas deletions in the pre-S1 or pre-S2 regions have been associated with the development of hepatocellular carcinoma. This review article will focus on the HBs Ag mutants and their biological and clinical implications. | Nicola Coppola Lorenzo Onorato Carmine Minichini Giovanni Di Caprio Mario Starace Caterina Sagnelli Evangelista Sagnelli | 2015 | World Journal of Hepatology2015，7，27： | 9 |
| 4 | New therapeutic vaccination strategies for the treatment of chronic hepatitis B显示文摘Chronic hepatitis B virus(CHB) is currently treated with either interferon-based or nucleot(s)idebased antiviral therapies.However,treatment with pegylated interferon alpha results in a durable antiviral response in only about 30%patients and is associated with side effects.Most patients receiving nucleot(s)ide analogue treatment do not establish long-term,durable control of Infection and have rebounding viremia after cessation of therapy.Thus,novel therapy strategies are necessary to achieve the induction of potent and durable antiviral immune responses of the patients which can maintain long-term control of viral replication.Therapeutic vaccination of HBV carriers is a promising strategy for the control of hepatitis B.Here the authors review new therapeutic vaccination strategies to treat chronic hepatitis B which may be introduced for patient treatment in the future. | Jia Liu Anna Kosinska Mengji Lu Michael Roggendorf | 2014 | Virologica Sinica2014，29，1： | 9 |
| 5 | A Case of Hepatitis B Reactivation in an Anti-HBs Positive,Anti-HBc Positive non-Hodgkin’s Lymphoma Patient显示文摘Dear Editor,We report a case of HBV reactivation in an anti-HBs positive, anti-HBc positive non-Hodgkin’s lymphoma patient. Hepatitis B virus (HBV) reactivation is a well-recognized complication of patients undergoing chemotherapy or immunosuppressive therapy for lymphomas. The presence of antibodies to the | Chunchen Wu Hui Shi Mengji Lu Yang Xu Xinwen Chen | 2013 | Virologica Sinica2013，28，1： | 2 |
| 6 | 顺铂对小鼠宫颈癌局部CD8^+T细胞的影响及可能机制显示文摘目的:探讨顺铂对小鼠宫颈癌局部CD8^+T细胞的影响及可能机制。方法:建立TC-1肿瘤细胞C57BL/6小鼠模型,分为对照组(4只)和顺铂组(4只),对照组给予磷酸盐缓冲溶液(PBS)100μl,顺铂组给予顺铂5 mg/kg,两组均腹腔注射,3天1次,共2次。免疫组化方法检测两组肿瘤组织中CD8阳性T细胞(CD8^+T)、程序性凋亡配体1(PD-L1)的表达,并对小鼠宫颈癌组织中CD8^+T细胞与PD-L1表达的相关性进行分析,同时采用流式细胞仪检测并比较两组脾单核淋巴细胞中CD4^+CD25^+T调节细胞(Treg)数量比例。结果:①顺铂组模型小鼠宫颈癌组织中CD8^+T表达的MOD值为3.24±0.39明显低于对照组4.70±0.28,差异有统计学意义(P<0.05);顺铂组PD-L1表达的MOD值为7.65±1.82高于对照组2.89±0.70,差异有统计学意义(P<0.05)。②小鼠肿瘤组织中CD8^+T细胞与PD-L1表达呈负相关(r=-0.61,P<0.05)。③顺铂组小鼠脾脏内单核淋巴细胞中Treg细胞数量(71.50±4.04)%低于对照组(87.00±6.06)%,差异有统计学意义(P<0.05)。结论:顺铂可增加宫颈癌组织PD-L1表达,减少宫颈癌组织局部CD8^+T细胞数量,抑制机体免疫内环境,并且顺铂对机体免疫的抑制作用可能并不来源于对Treg细胞的影响。应用PD-L1抗体阻断顺铂诱发的PD-L1表达可能可促进顺铂的化疗效果。 | 张素仙 魏洁 陈艳 冷天艳 张琴 杨丽华 | 2016 | 实用妇产科杂志2016，32，11： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员